Gene expression profiling has been successfully employed in patients with breast cancer to identify molecular subtypes (basal/triple negative, HER2+, luminal A, and luminal B) that behave clinically as distinct disease entities [1]. This evidence concerns the gene ERBB2 and breast carcinoma.